Drug intelligence / Profile preview

bis(3-amino-2-pyridine) diselenide

Development stage: Preclinical
Modality: Small Molecules

Overview

Bis(3-amino-2-pyridine) diselenide (BAPD) is a compound that has shown potential in improving psychiatric disorders comorbid with atopic dermatitis by regulating inflammatory and oxidative stress in mice. It exhibits anxiolytic and antidepressant-like effects and improves cutaneous damage and scratching behavior. The mechanism involves modulating inflammatory and oxidative markers, as well as restoring Na+, K+-ATPase activity and corticosterone levels.

Other names: BAPD

Beyond the preview

Go deeper on bis(3-amino-2-pyridine) diselenide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bis(3-amino-2-pyridine) diselenide.

Explore the full profile